Scientific deep-dive

What Is Petrelintide? Zealand's Long-Acting Amylin Analog

Petrelintide is Zealand Pharma's investigational long-acting amylin analog, with published human data through phase 2. We cover what amylin analogs are for, how early 'early' really is, and why early-phase figures cannot be compared to phase 3 results.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
5 min read·4 citations

Petrelintide is an investigational long-acting human amylin analog from Zealand Pharma. Like cagrilintide, it acts on the amylin system rather than the GLP-1 system — a genuinely different mechanism, not a stronger version of the drugs already on the market [3]. It is at an earlier stage than most compounds people ask about: the published human data run from phase 1 [2] to one phase 2 trial [4], and it has no approval anywhere.

What amylin analogs are for

Amylin is released with insulin from pancreatic beta cells and reduces meal size through its own receptor pathway. The interest in analogs of it is partly about added weight loss and substantially about tolerability: the search for better-tolerated weight-loss drugs is the explicit framing in the review literature [3], because GLP-1 discontinuation is frequently driven by gastrointestinal side effects rather than lack of effect.

Petrelintide was engineered for potency, stability and a long half-life so it can be dosed weekly [1] — the same design problem cagrilintide solves, approached by a different company.

How early is early

The published clinical evidence starts with two randomized, controlled phase 1 trials reporting safety, tolerability, pharmacokinetics and pharmacodynamics for weight management [2]. Phase 1 trials are designed to answer whether a drug is tolerable and how the body handles it — not whether it works better than an existing treatment.

The first efficacy data come from ZUPREME 1, a 42-week phase 2 trial published in Lancet Diabetes & Endocrinology in 2026 that randomly assigned 493 adults without type 2 diabetes to weekly petrelintide (maintenance doses of 1.0 to 9.0 mg) or placebo [4]. At the primary 28-week endpoint, mean weight change by the efficacy estimand was −7.9% to −9.8% across doses versus −1.7% on placebo, with reductions of up to −10.7% by week 42. Nausea was the most common adverse event (20% vs 6% on placebo); vomiting occurred in 3% vs 6%.

What early-phase trials cannot tell you. Weight-loss percentages quoted from early-phase work are not comparable to the phase 3 figures you have seen for semaglutide or tirzepatide. Different sample sizes, durations, and endpoints — and early-phase estimates move, often downward, as trials get larger. Treat any petrelintide-versus-Wegovy comparison as speculation.

It is not available, in any form

Petrelintide has no approval and no prescription route. As with every unapproved compound in this class, anything offered for sale under the name is unapproved material rather than a trial drug — and with only phase 1 and phase 2 trials published, the total human safety experience is smaller than for almost anything else being sold that way.

For Eli Lilly's amylin candidate, see what is eloralintide?, which covers its 48-week phase 2 trial.

Frequently Asked Questions

No. It is investigational, with published human data through phase 2. There is no approval and no prescription route anywhere.
No, but they are the same class. Both are long-acting amylin analogs designed for weekly dosing; petrelintide is Zealand Pharma's and cagrilintide is Novo Nordisk's, and cagrilintide is much further along.
No. It acts on amylin receptors, a separate hormone system. That is the point of the class — a different mechanism, with the hope of better tolerability.

References

  1. 1.Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. PMID: 41217931.
  2. 2.Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. PMID: 42017294.
  3. 3.Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. PMID: 42452898.
  4. 4.Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42810355.

What Is Cagrilintide? The Amylin Analog Behind CagriSema

Cagrilintide is a once-weekly amylin analog from Novo Nordisk and the other half of CagriSema. Neither has FDA approval. We cover what amylin analogs actually are, the pooled trial evidence across 5,425 participants, and why there is no cagrilintide dosage chart to follow.

6 min read

What Is Eloralintide? Lilly's Amylin Weight-Loss Drug Explained

Eloralintide is Eli Lilly's investigational once-weekly amylin drug. In a 48-week phase 2 trial people lost about 20% of body weight on higher doses, with nausea and fatigue as the main side effects. How it works, the trial results, and the phase 3 timeline.

7 min read

Cagrilintide: The Amylin Analogue Behind CagriSema — What the Evidence Shows

Cagrilintide is Novo Nordisk's investigational long-acting amylin analog and the amylin half of CagriSema. The phase 2 monotherapy trial showed about -10.8% weight loss at 26 weeks. What it is, the trial data, and what it means for patients.

8 min read

REDEFINE: The Full CagriSema Trial Program (2026)

The full CagriSema REDEFINE program: REDEFINE 1 (22.7% adherent weight loss), REDEFINE 2 in diabetes, and the REDEFINE 4 head-to-head miss versus tirzepatide.

13 min read

Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs to Watch

Three challenger GLP-1 drugs not made by Lilly or Novo: survodutide (Boehringer Ingelheim and Zealand), maridebart cafraglutide (Amgen's MariTide), and ecnoglutide (Sciwind). This guide covers the published phase 2 and 3 data and mechanisms for each, and where they fit.

11 min read

Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review

Bimagrumab is an investigational antibody that blocks ActRII to build muscle while cutting fat — the opposite of GLP-1 muscle loss. Phase 2 evidence: -20.5% fat, +3.6% lean, plus the BELIEVE bimagrumab + semaglutide trial.

9 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

Pricing Compare

Get started →
7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Read full review →

Pricing Compare

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

Pricing Compare

Get started →